ArticleJournal of thoracic disease2026
Risk factors for treatment failure of drug-resistant pulmonary tuberculosis: results from a two-decade data analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major public health challenge worldwide, particularly in Eastern Europe, where high disease burden and complex treatment regimens contribute to suboptimal outcomes. Lithuania has historically reported high rates of pulmonary DR-TB; however, data on long-term treatment outcomes and their determinants over extended periods are limited. This study evaluated long-term treatment outcomes among adults with pulmonary DR-TB in Lithuania over a 22-year period and assessed associations between treatment outcomes, individual risk factors, and temporal trends. Methods: A retrospective cohort analysis was conducted using data from the National Tuberculosis Information System for 2000-2021. The study included 5,761 adults with DR-TB, categorized into three periods: Period I (2000-2007), Period II (2008-2015), and Period III (2016-2021). Treatment outcomes were classified as successful (treatment completion with recovery) or unsuccessful [treatment failure, progression to chronic TB, death before completion, or transition from multidrug-resistant tuberculosis (MDR-TB) to extensively drug-resistant tuberculosis (XDR-TB)]. Associations between outcomes and risk factors such as smoking, alcohol and substance use, comorbidities, and sociodemographic variables were examined using multivariate analysis. Results: Treatment success rates increased steadily across periods (66.2%, 68.5%, and 79.5%), while mortality rates declined (30.7%, 29.5%, and 20.1%). Non-lethal treatment failure rates decreased markedly (3.0%, 2.0%, and 0.3%). Treatment failure was significantly associated with low body mass index, male gender, unemployment, homelessness, tobacco and alcohol use, substance abuse, and comorbidities including cancer, cardiovascular and chronic lung disease, diabetes mellitus, human immunodeficiency virus (HIV) infection, and renal failure. Conclusions: Treatment outcomes of DR-TB in Lithuania have shown improvement over a 22-year period. Successful treatment outcomes were strongly influenced by a combination of clinical, behavioral, and socioeconomic factors, underscoring the complexity of DR-TB management. The relative importance of these components may vary for each individual patient. Incorporating multifaceted strategies, such as psychological support, social assistance (including access to food and shelter), and employment opportunities, into the national DR-TB control framework could enhance health system responsiveness and reduce inequities in care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.